Top

Journal of Neuroinflammation

Published in:

Open Access 01-12-2016 | Research

α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology

Authors: Josefine R. Christiansen, Mads N. Olesen, Daniel E. Otzen, Marina Romero-Ramos, Vanesa Sanchez-Guajardo

Published in: Journal of Neuroinflammation | Issue 1/2016

Abstract

Background

Passive and active immunization with α-synuclein has been shown to be neuroprotective in animal models of Parkinson’s disease. We have previously shown that vaccination with α-synuclein, long before α-synuclein-induced brain pathology, prevents striatal degeneration by inducing regulatory T cell infiltration in parenchyma and antibody deposition on α-synuclein overexpressing neurons. However, the effect of peripheral α-synuclein on the immune system is unknown, as are the mechanistic changes induced in the CD4 T cell population during successful neuroprotective animal studies. We have studied the changes induced by vaccination with α-synuclein in the CD4 T cell pool and its impact on brain microglia to understand the immune mechanisms behind successful vaccination strategies in Parkinson’s disease animal models.

Methods

Mice were immunized with WT or nitrated α-synuclein at a dose equivalent to the one used in our previous successful vaccination strategy and at a higher dose to determine potential dose-dependent effects. Animals were re-vaccinated 4 weeks after and sacrificed 5 days later. These studies were conducted in naive animals in the absence of human α-synuclein expression.

Results

The CD4 T cell response was modulated by α-synuclein in a dose-dependent manner, in particular the regulatory T cell population. Low-dose α-synuclein induced expansion of naive (Foxp3 + CCR6-CD127lo/neg) and dopamine receptor type D3+ regulatory T cells, as well as an increase in Stat5 protein levels. On the other hand, high dose promoted activation of regulatory T cells (Foxp3CCR6 + CD127lo/neg), which were dopamine receptor D2+D3-, and induced up-regulation of Stat5 and production of anti-α-synuclein antibodies. These effects were specific to the variant of α-synuclein used as the pathology-associated nitrated form induced distinct effects at both doses. The changes observed in the periphery after vaccination with low-dose α-synuclein correlated with an increase in CD154+, CD103+, and CD54+ microglia and the reduction of CD200R+ microglia. This resulted in the induction of a polarized tolerogenic microglia population that was CD200R-CD54CD103CD172a+ (82 % of total microglia).

Conclusions

We have shown for the first time the mechanisms behind α-synuclein vaccination and, importantly, how we can modulate microglia’s phenotype by regulating the CD4 T cell pool, thus shedding invaluable light on the design of neuroimmunoregulatory therapies for Parkinson’s disease.

Available only for authorised users

Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron. 2005;46(6):857–68. doi:10.1016/j.neuron.2005.05.010.CrossRefPubMed

Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. 2011;6(4):e19338. doi:10.1371/journal.pone.0019338.CrossRefPubMedPubMedCentral

Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M. Alpha-synuclein vaccination prevents the accumulation of Parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J Neuropathol Exp Neurol. 2013;72(7):624–45. doi:10.1097/NEN.0b013e31829768d2.CrossRefPubMed

Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol. 2010;184(5):2261–71. doi:10.4049/jimmunol.0901852.CrossRefPubMedPubMedCentral

Saha B, Mondal AC, Majumder J, Basu S, Dasgupta PS. Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation. 2001;9(1):23–33.CrossRefPubMed

Nagai Y, Ueno S, Saeki Y, Soga F, Hirano M, Yanagihara T. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson’s disease. Neurology. 1996;46(3):791–5.CrossRefPubMed

Levite M, Chowers Y, Ganor Y, Besser M, Hershkovits R, Cahalon L. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function. Eur J Immunol. 2001;31(12):3504–12. doi:10.1002/1521-4141(200112)31:12<3504::AID-IMMU3504>3.0.CO;2-F.CrossRefPubMed

Besser MJ, Ganor Y, Levite M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. J Neuroimmunol. 2005;169(1-2):161–71. doi:10.1016/j.jneuroim.2005.07.013.CrossRefPubMed

Ghosh MC, Mondal AC, Basu S, Banerjee S, Majumder J, Bhattacharya D, et al. Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int Immunopharmacol. 2003;3(7):1019–26. doi:10.1016/S1567-5769(03)00100-0.CrossRefPubMed

10.

Sarkar C, Das S, Chakroborty D, Chowdhury UR, Basu B, Dasgupta PS, et al. Cutting edge: stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J Immunol. 2006;177(11):7525–9.CrossRefPubMed

11.

Pacheco R, Prado CE, Barrientos MJ, Bernales S. Role of dopamine in the physiology of T-cells and dendritic cells. J Neuroimmunol. 2009;216(1-2):8–19. doi:10.1016/j.jneuroim.2009.07.018.CrossRefPubMed

12.

Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S. The immunoregulatory role of dopamine: an update. Brain Behav Immun. 2010;24(4):525–8. doi:10.1016/j.bbi.2009.10.015.CrossRefPubMedPubMedCentral

13.

Romero-Ramos M, von Euler CM, Sanchez-Guajardo V. Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance? Hum Vaccin Immunotherapeutics. 2014;10(4):852–67.CrossRef

14.

Nakano K, Higashi T, Takagi R, Hashimoto K, Tanaka Y, Matsushita S. Dopamine released by dendritic cells polarizes Th2 differentiation. Int Immunol. 2009;21(6):645–54. doi:10.1093/intimm/dxp033.CrossRefPubMed

15.

Prado C, Contreras F, Gonzalez H, Diaz P, Elgueta D, Barrientos M, et al. Stimulation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity. J Immunol. 2012;188(7):3062–70. doi:10.4049/jimmunol.1103096.CrossRefPubMed

16.

Cosentino M, Fietta AM, Ferrari M, Rasini E, Bombelli R, Carcano E, et al. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood. 2007;109(2):632–42. doi:10.1182/blood-2006-01-028423.CrossRefPubMed

17.

Leong SL, Cappai R, Barnham KJ, Pham CL. Modulation of alpha-synuclein aggregation by dopamine: a review. Neurochem Res. 2009;34(10):1838–46. doi:10.1007/s11064-009-9986-8.CrossRefPubMed

18.

Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J Neural Transm. 2006;113(10):1435–9. doi:10.1007/s00702-005-0427-9.CrossRefPubMed

19.

Mollenhauer B. Quantification of alpha-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson’s disease? Parkinsonism Relat Disord. 2014;20 Suppl 1:S76–9. doi:10.1016/S1353-8020(13)70020-8.CrossRefPubMed

20.

Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009;106(31):13010–5. doi:10.1073/pnas.0903691106.CrossRefPubMedPubMedCentral

21.

Lee SJ, Desplats P, Lee HJ, Spencer B, Masliah E. Cell-to-cell transmission of alpha-synuclein aggregates. Methods Mol Biol. 2012;849:347–59. doi:10.1007/978-1-61779-551-0_23.CrossRefPubMed

22.

Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949–53. doi:10.1126/science.1227157.CrossRefPubMedPubMedCentral

23.

Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, Papadimitriou A, et al. Autoantibodies to alpha-synuclein in inherited Parkinson’s disease. J Neurochem. 2007;101(3):749–56. doi:10.1111/j.1471-4159.2006.04365.x.CrossRefPubMedPubMedCentral

24.

Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, et al. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis. 2011;26(1):171–9. doi:10.3233/JAD-2011-110221.PubMed

25.

Besong-Agbo D, Wolf E, Jessen F, Oechsner M, Hametner E, Poewe W, et al. Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology. 2013;80(2):169–75. doi:10.1212/WNL.0b013e31827b90d1.CrossRefPubMed

26.

Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord. 2005;11(8):493–8. doi:10.1016/j.parkreldis.2005.07.005.CrossRefPubMed

27.

Bas J, Calopa M, Mestre M, Mollevi DG, Cutillas B, Ambrosio S, et al. Lymphocyte populations in Parkinson’s disease and in rat models of parkinsonism. J Neuroimmunol. 2001;113(1):146–52. doi:S0165-5728(00)00422-7 [pii].CrossRefPubMed

28.

Alberio T, Pippione AC, Zibetti M, Olgiati S, Cecconi D, Comi C, et al. Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson’s disease. Scientific reports. 2012;2:953. doi:10.1038/srep00953.CrossRefPubMedPubMedCentral

29.

Stevens CH, Rowe D, Morel-Kopp MC, Orr C, Russell T, Ranola M, et al. Reduced T helper and B lymphocytes in Parkinson’s disease. J Neuroimmunol. 2012;252(1-2):95–9. doi:10.1016/j.jneuroim.2012.07.015.CrossRefPubMed

30.

Gruden MA, Sewell RD, Yanamandra K, Davidova TV, Kucheryanu VG, Bocharov EV, et al. Immunoprotection against toxic biomarkers is retained during Parkinson’s disease progression. J Neuroimmunol. 2011;233(1-2):221–7. doi:10.1016/j.jneuroim.2010.12.001.CrossRefPubMed

31.

Prigione A, Begni B, Galbussera A, Beretta S, Brighina L, Garofalo R, et al. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson’s disease: negative correlation with levodopa dosage. Neurobiol Dis. 2006;23(1):36–43. doi:10.1016/j.nbd.2006.01.013.CrossRefPubMed

32.

Prigione A, Isaias IU, Galbussera A, Brighina L, Begni B, Andreoni S, et al. Increased oxidative stress in lymphocytes from untreated Parkinson’s disease patients. Parkinsonism Relat Disord. 2009;15(4):327–8. doi:10.1016/j.parkreldis.2008.05.013.CrossRefPubMed

33.

Battisti C, Formichi P, Radi E, Federico A. Oxidative-stress-induced apoptosis in PBLs of two patients with Parkinson disease secondary to alpha-synuclein mutation. J Neurol Sci. 2008;267(1-2):120–4. doi:10.1016/j.jns.2007.10.012.CrossRefPubMed

34.

Calopa M, Bas J, Callen A, Mestre M. Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol Dis. 2010;38(1):1–7. doi:10.1016/j.nbd.2009.12.017.CrossRefPubMed

35.

Shin EC, Cho SE, Lee DK, Hur MW, Paik SR, Park JH, et al. Expression patterns of alpha-synuclein in human hematopoietic cells and in Drosophila at different developmental stages. Molecules and cells. 2000;10(1):65–70.CrossRefPubMed

36.

Nakaso K, Tajima N, Ito S, Teraoka M, Yamashita A, Horikoshi Y, et al. Dopamine-mediated oxidation of methionine 127 in alpha-synuclein causes cytotoxicity and oligomerization of alpha-synuclein. PLoS One. 2013;8(2):e55068. doi:10.1371/journal.pone.0055068.CrossRefPubMedPubMedCentral

37.

Lee HJ, Baek SM, Ho DH, Suk JE, Cho ED, Lee SJ. Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Exp Mol Med. 2011;43(4):216–22. doi:10.3858/emm.2011.43.4.026.CrossRefPubMedPubMedCentral

38.

Ha Y, Yang A, Lee S, Kim K, Liew H, Lee SH, et al. Dopamine and Cu+/2+ can induce oligomerization of alpha-synuclein in the absence of oxygen: two types of oligomerization mechanisms for alpha-synuclein and related cell toxicity studies. J Neurosci Res. 2014;92(3):359–68. doi:10.1002/jnr.23323.CrossRefPubMed

39.

Tavassoly O, Nokhrin S, Dmitriev OY, Lee JS. Cu(II) and dopamine bind to alpha-synuclein and cause large conformational changes. The FEBS journal. 2014;281(12):2738–53. doi:10.1111/febs.12817.CrossRefPubMed

40.

Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, et al. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One. 2008;3(1):e1376. doi:10.1371/journal.pone.0001376.CrossRefPubMedPubMedCentral

41.

Reynolds AD, Stone DK, Mosley RL, Gendelman HE. Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol. 2009;182(7):4137–49. doi:10.4049/jimmunol.0803982.CrossRefPubMedPubMedCentral

42.

Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci U S A. 2005;102(14):5126–31. doi:10.1073/pnas.0501701102.CrossRefPubMedPubMedCentral

43.

Nielsen SB, Macchi F, Raccosta S, Langkilde AE, Giehm L, Kyrsting A, et al. Wildtype and A30P mutant alpha-synuclein form different fibril structures. PLoS One. 2013;8(7):e67713. doi:10.1371/journal.pone.0067713.CrossRefPubMedPubMedCentral

44.

Smith EL, Finney HM, Nesbitt AM, Ramsdell F, Robinson MK. Splice variants of human FOXP3 are functional inhibitors of human CD4+ T-cell activation. Immunology. 2006;119(2):203–11. doi:10.1111/j.1365-2567.2006.02425.x.CrossRefPubMedPubMedCentral

45.

Armentero MT, Levandis G, Nappi G, Bazzini E, Blandini F. Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund’s adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson’s disease. Neurobiol Dis. 2006;24(3):492–505. doi:10.1016/j.nbd.2006.08.016.CrossRefPubMed

46.

Yong J, Lacan G, Dang H, Hsieh T, Middleton B, Wasserfall C, et al. BCG vaccine-induced neuroprotection in a mouse model of Parkinson’s disease. PLoS One. 2011;6(1):e16610. doi:10.1371/journal.pone.0016610.CrossRefPubMedPubMedCentral

47.

Outeiro TF, Klucken J, Bercury K, Tetzlaff J, Putcha P, Oliveira LM, et al. Dopamine-induced conformational changes in alpha-synuclein. PLoS One. 2009;4(9):e6906. doi:10.1371/journal.pone.0006906.CrossRefPubMedPubMedCentral

48.

Cappai R, Leck SL, Tew DJ, Williamson NA, Smith DP, Galatis D, et al. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 2005;19(10):1377–9. doi:10.1096/fj.04-3437fje.PubMed

49.

Conway KA, Rochet JC, Bieganski RM, Lansbury Jr PT. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001;294(5545):1346–9. doi:10.1126/science.1063522.CrossRefPubMed

50.

Gonzalez H, Contreras F, Prado C, Elgueta D, Franz D, Bernales S, et al. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson’s disease. J Immunol. 2013;190(10):5048–56. doi:10.4049/jimmunol.1203121.CrossRefPubMed

51.

Tinsley RB, Bye CR, Parish CL, Tziotis-Vais A, George S, Culvenor JG, et al. Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol. 2009;66(4):472–84. doi:10.1002/ana.21716.CrossRefPubMed

52.

Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009;10(5):514–23. doi:10.1038/ni.1716.CrossRefPubMed

53.

Allakhverdi Z, Fitzpatrick D, Boisvert A, Baba N, Bouguermouh S, Sarfati M, et al. Expression of CD103 identifies human regulatory T-cell subsets. J Allergy Clin Immunol. 2006;118(6):1342–9. doi:10.1016/j.jaci.2006.07.034.CrossRefPubMed

54.

Huang G, Wang Y, Chi H. Control of T cell fates and immune tolerance by p38alpha signaling in mucosal CD103+ dendritic cells. J Immunol. 2013;191(2):650–9. doi:10.4049/jimmunol.1300398.CrossRefPubMedPubMedCentral

55.

Simonetta F, Chiali A, Cordier C, Urrutia A, Girault I, Bloquet S, et al. Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. Eur J Immunol. 2010;40(9):2528–38. doi:10.1002/eji.201040531.CrossRefPubMed

56.

Di Caro V, D’Anneo A, Phillips B, Engman C, Harnaha J, Lakomy R, et al. Interleukin-7 matures suppressive CD127(+) forkhead box P3 (FoxP3)(+) T cells into CD127(-) CD25(high) FoxP3(+) regulatory T cells. Clin Exp Immunol. 2011;165(1):60–76. doi:10.1111/j.1365-2249.2011.04334.x.CrossRefPubMedPubMedCentral

57.

Beyer M, Classen S, Endl E, Kochanek M, Weihrauch MR, Debey-Pascher S, et al. Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3. Clin Dev Immunol. 2011;2011:734036. doi:10.1155/2011/734036.CrossRefPubMedPubMedCentral

58.

Paillusson S, Clairembault T, Biraud M, Neunlist M, Derkinderen P. Activity-dependent secretion of alpha-synuclein by enteric neurons. J Neurochem. 2013;125(4):512–7. doi:10.1111/jnc.12131.CrossRefPubMed

59.

Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis. 2008;5(2):55–9. doi:10.1159/000112832.CrossRefPubMed

60.

Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M. Neuroimmunological processes in Parkinson’s disease and their relation to alpha-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN neuro. 2013;5(2):113–39. doi:10.1042/AN20120066.CrossRefPubMed

61.

Kim S, Jeon BS, Heo C, Im PS, Ahn TB, Seo JH, et al. Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson’s disease. FASEB J. 2004;18(13):1615–7. doi:10.1096/fj.04-1917fje.PubMed

62.

Gardai SJ, Mao W, Schule B, Babcock M, Schoebel S, Lorenzana C, et al. Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson’s disease. PLoS One. 2013;8(8):e71634. doi:10.1371/journal.pone.0071634.CrossRefPubMedPubMedCentral

63.

Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. 2005;6(12):1219–27. doi:10.1038/ni1265.CrossRefPubMed

64.

Kleinewietfeld M, Puentes F, Borsellino G, Battistini L, Rotzschke O, Falk K. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood. 2005;105(7):2877–86. doi:10.1182/blood-2004-07-2505.CrossRefPubMed

65.

Yamazaki T, Yang XO, Chung Y, Fukunaga A, Nurieva R, Pappu B, et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol. 2008;181(12):8391–401.CrossRefPubMedPubMedCentral

66.

Comerford I, Bunting M, Fenix K, Haylock-Jacobs S, Litchfield W, Harata-Lee Y, et al. An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation?: CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. Bioessays. 2010;32(12):1067–76. doi:10.1002/bies.201000063.CrossRefPubMed

67.

Hedrick MN, Lonsdorf AS, Hwang ST, Farber JM. CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets. 2010;14(9):911–22. doi:10.1517/14728222.2010.504716.CrossRefPubMedPubMedCentral

68.

Pacheco R, Riquelme E, Kalergis AM. Emerging evidence for the role of neurotransmitters in the modulation of T cell responses to cognate ligands. Cent Nerv Syst Agents Med Chem. 2010;10(1):65–83.CrossRefPubMed

69.

Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol. 2008;8(4):460–71. doi:10.1016/j.coph.2008.05.001.CrossRefPubMed

70.

Beraud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA, et al. Microglial activation and antioxidant responses induced by the Parkinson’s disease protein alpha-synuclein. J Neuroimmune Pharmacol. 2013;8(1):94–117. doi:10.1007/s11481-012-9401-0.CrossRefPubMedPubMedCentral

71.

Ferreira TB, Kasahara TM, Barros PO, Vieira MM, Bittencourt VC, Hygino J, et al. Dopamine up-regulates Th17 phenotype from individuals with generalized anxiety disorder. J Neuroimmunol. 2011;238(1-2):58–66. doi:10.1016/j.jneuroim.2011.06.009.CrossRefPubMed

72.

Kipnis J, Cardon M, Avidan H, Lewitus GM, Mordechay S, Rolls A, et al. Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. J Neurosci. 2004;24(27):6133–43. doi:10.1523/JNEUROSCI.0600-04.2004.CrossRefPubMed

73.

Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, Matsushita S. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun. 2008;373(2):286–91. doi:10.1016/j.bbrc.2008.06.012.CrossRefPubMed

74.

Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev. 2001;53(1):119–33.PubMed

75.

Wu J, Hablitz JJ. Cooperative activation of D1 and D2 dopamine receptors enhances a hyperpolarization-activated inward current in layer I interneurons. J Neurosci. 2005;25(27):6322–8. doi:10.1523/JNEUROSCI.1405-05.2005.CrossRefPubMed

76.

Malmberg A, Jackson DM, Eriksson A, Mohell N. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol. 1993;43(5):749–54.PubMed

77.

Franz D, Contreras F, Gonzalez H, Prado C, Elgueta D, Figueroa C, et al. Dopamine receptors D3 and D5 regulate CD4(+)T-cell activation and differentiation by modulating ERK activation and cAMP production. J Neuroimmunol. 2015;284:18–29. doi:10.1016/j.jneuroim.2015.05.003.CrossRefPubMed

78.

Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6(4):193–201. doi:10.1038/nrneurol.2010.17.CrossRefPubMed

79.

Doorn KJ, Lucassen PJ, Boddeke HW, Prins M, Berendse HW, Drukarch B, et al. Emerging roles of microglial activation and non-motor symptoms in Parkinson’s disease. Prog Neurobiol. 2012;98(2):222–38. doi:10.1016/j.pneurobio.2012.06.005.CrossRefPubMed

80.

Hanisch UK. Functional diversity of microglia—how heterogeneous are they to begin with? Front Cell Neurosci. 2013;7:65. doi:10.3389/fncel.2013.00065.CrossRefPubMedPubMedCentral

81.

Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10(11):1387–94. doi:10.1038/nn1997.CrossRefPubMed

82.

de Haas AH, Boddeke HW, Biber K. Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. Glia. 2008;56(8):888–94. doi:10.1002/glia.20663.CrossRefPubMed

83.

Garcia-Esparcia P, Llorens F, Carmona M, Ferrer I. Complex deregulation and expression of cytokines and mediators of the immune response in Parkinson’s disease brain is region dependent. Brain Pathol. 2014;24(6):584–98. doi:10.1111/bpa.12137.CrossRefPubMed

84.

Mitra S, Chakrabarti N, Bhattacharyya A. Differential regional expression patterns of alpha-synuclein, TNF-alpha, and IL-1beta; and variable status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment. J Neuroinflammation. 2011;8:163. doi:10.1186/1742-2094-8-163.CrossRefPubMedPubMedCentral

85.

Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, et al. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol. 2012;237(2):318–34. doi:10.1016/j.expneurol.2012.06.025.CrossRefPubMedPubMedCentral

86.

Ulusoy A, Di Monte DA. alpha-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. Mol Neurobiol. 2013;47(2):484–94. doi:10.1007/s12035-012-8329-y.CrossRefPubMed

87.

Barclay AN, Brown MH. The SIRP family of receptors and immune regulation. Nat Rev Immunol. 2006;6(6):457–64. doi:10.1038/nri1859.CrossRefPubMed

88.

Smith RE, Patel V, Seatter SD, Deehan MR, Brown MH, Brooke GP, et al. A novel MyD-1 (SIRP-1alpha) signaling pathway that inhibits LPS-induced TNFalpha production by monocytes. Blood. 2003;102(7):2532–40. doi:10.1182/blood-2002-11-3596.CrossRefPubMed

89.

Zhang H, Li F, Yang Y, Chen J, Hu X. SIRP/CD47 signaling in neurological disorders. Brain Res. 2015;1623:74–80. doi:10.1016/j.brainres.2015.03.012.CrossRefPubMed

90.

Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol. 1990;144(12):4579–86.PubMed

91.

Flores-Langarica A, Marshall JL, Hitchcock J, Cook C, Jobanputra J, Bobat S, et al. Systemic flagellin immunization stimulates mucosal CD103+ dendritic cells and drives Foxp3+ regulatory T cell and IgA responses in the mesenteric lymph node. J Immunol. 2012;189(12):5745–54. doi:10.4049/jimmunol.1202283.CrossRefPubMed

92.

Annacker O, Coombes JL, Malmstrom V, Uhlig HH, Bourne T, Johansson-Lindbom B, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med. 2005;202(8):1051–61. doi:10.1084/jem.20040662.CrossRefPubMedPubMedCentral

93.

Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015. doi:10.1038/nature14432.

94.

Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson’s disease. Brain. 2005;128(Pt 11):2665–74. doi:10.1093/brain/awh625.CrossRefPubMed

95.

Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease. J Leukoc Biol. 2007;82(5):1083–94. doi:10.1189/jlb.0507296.CrossRefPubMed

96.

Laurie C, Reynolds A, Coskun O, Bowman E, Gendelman HE, Mosley RL. CD4+ T cells from copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J Neuroimmunol. 2007;183(1-2):60–8. doi:10.1016/j.jneuroim.2006.11.009.CrossRefPubMed

97.

Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119(1):182–92. doi:10.1172/JCI36470.PubMedPubMedCentral

98.

Baruch K, Rosenzweig N, Kertser A, Deczkowska A, Sharif AM, Spinrad A, et al. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer’s disease pathology. Nat Commun. 2015;6:7967. doi:10.1038/ncomms8967.CrossRefPubMedPubMedCentral

99.

Couch Y, Alvarez-Erviti L, Sibson NR, Wood MJ, Anthony DC. The acute inflammatory response to intranigral alpha-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation. 2011;8:166. doi:10.1186/1742-2094-8-166.CrossRefPubMedPubMedCentral

100.

Lochner M, Peduto L, Cherrier M, Sawa S, Langa F, Varona R, et al. In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t + T cells. J Exp Med. 2008;205(6):1381–93. doi:10.1084/jem.20080034.CrossRefPubMedPubMedCentral

Title: α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology
Authors: Josefine R. Christiansen
Mads N. Olesen
Daniel E. Otzen
Marina Romero-Ramos
Vanesa Sanchez-Guajardo
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Journal of Neuroinflammation / Issue 1/2016
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-016-0532-8

At a glance: The STEP trials

Springer Medicine

α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Early life overfeeding impairs spatial memory performance by reducing microglial sensitivity to learning

Electroconvulsive shock attenuated microgliosis and astrogliosis in the hippocampus and ameliorated schizophrenia-like behavior of Gunn rat

Erratum to: P2X7R blockade prevents NLRP3 inflammasome activation and brain injury in a rat model of intracerebral hemorrhage: involvement of peroxynitrite

LRP1 modulates the microglial immune response via regulation of JNK and NF-κB signaling pathways

Secreted herpes simplex virus-2 glycoprotein G alters thermal pain sensitivity by modifying NGF effects on TRPV1

Etifoxine improves sensorimotor deficits and reduces glial activation, neuronal degeneration, and neuroinflammation in a rat model of traumatic brain injury